Business

The Canadian pharmaceutical manufacturer says it is supplying 26 Australian clinics with naturally derived psilocybin and is targeting further growth...

The Australian-founded biotechnology company is progressing three investigational treatments, including a synthetic psilocybin therapy for generalised anxiety disorder, as its...

New Zealand medicinal cannabis company Rua Bioscience has signed a distribution agreement with PharmAla Biotech, following the country's first approvals...

The US pharmaceutical giant has put $906 million behind a next-generation psychedelic for depression, giving one of the industry’s largest...

As psychedelic medicine moves towards pharmaceutical development, Incannex is attempting to take synthetic psilocybin through the clinical, regulatory and commercial...

Entropy Neurodynamics, GH Research and Helus Pharma are taking different approaches to a shared challenge: developing psychedelic medicines that can...

Emyria has begun treating its first patients at a new Sydney clinic, extending its Empax mental health services into New...

Melbourne-based Entropy Neurodynamics is advancing an intravenous psilocin programme spanning binge eating disorder, depression and other neuropsychiatric conditions, with recent...

Optimi Health has completed production of a new batch of 5mg naturally derived psilocybin capsules, with the same batch set...

Australian psychedelic medicine company Emyria has brought former US Secretary of Veterans Affairs Dr David Shulkin into its strategy as...